Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HaleonHLN -2.37%70 Return-on-Tangible-Asset is 21.96% as of Jun. 2026, which is 40% above its 10-year median of 15.67. GuruFocus rates HLN with a GF Score™ of 70/100 and a GF Value™ of $10.13 (Fairly Valued). The stock has 2 warning signs investors should review. Among 1,009 Drug Manufacturers companies, Haleon ranks better than 95.84% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Haleon's annualizedNet Income for the quarter that ended in Jun. 2026 was $2,032 Mil. Haleon's average total tangible assets for the quarter that ended in Jun. 2026 was $9,254 Mil. Therefore, Haleon's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2026 was 21.96%.
The historical rank and industry rank for Haleon's Return-on-Tangible-Asset or its related term are showing as below:
HLN'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 8.51 Med: 15.67 Max: 23.97
Current: 23.97
During the past 7 years, Haleon's highest Return-on-Tangible-Asset was 23.97%. The lowest was 8.51%. And the median was 15.67%.
HLN's Return-on-Tangible-Asset is ranked better than 95.84% of 1009
companies
in the Drug Manufacturers industry
Industry Median: 3.13
vs HLN: 23.97
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Haleon Return-on-Tangible-Asset Related Terms
Haleon Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Haleon's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HLN vs ZTS, UTHR, VTRS: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Haleon's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Haleon Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Haleon's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Haleon's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Jun. 2026) net income data.
What does a Return-on-Tangible-Asset of 21.96% mean?
Haleon (HLN) has a Return-on-Tangible-Asset of 21.96% as of Jun. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Haleon and its competitors. This is 40% above median its historical median of 15.67. Over the past decade, Haleon's Return-on-Tangible-Asset has ranged from 8.51 to 23.97. According to the industry distribution chart, Haleon ranks #42 out of 1009 companies in the Drug Manufacturers industry, placing it in the top 4.2%.
Is Haleon's Return-on-Tangible-Asset too high?
Haleon's current Return-on-Tangible-Asset of 21.96% is 40% above median its 10-year median of 15.67. Over the past 10 years, this metric has ranged from a low of 8.51 to a high of 23.97. The Drug Manufacturers industry median Return-on-Tangible-Asset is 3.13. Haleon's value of 21.96% is 601.6% above this industry median. Based on the distribution chart, Haleon ranks #42 out of 1009 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Haleon has a GF Score™ of 70/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Haleon's Return-on-Tangible-Asset compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Haleon ranks #42 out of 1009 companies for Return-on-Tangible-Asset. This places Haleon in the top 4% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 3.13. Haleon's value of 21.96% is 601.6% above this benchmark. Historically, Haleon's own Return-on-Tangible-Asset has ranged from 8.51 to 23.97 over the past decade. While the company's 10-year median is 15.67 vs. the industry median of 3.13, Haleon has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.13, based on 1,009 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Haleon's current Return-on-Tangible-Asset of 21.96% is 601.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Haleon and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Haleon's current Return-on-Tangible-Asset is 21.96%, which is 40% above median its own 10-year median of 15.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Haleon stock overvalued right now?
Based on GuruFocus' analysis, Haleon (HLN) is currently considered Fairly Valued. The stock's GF Value™ is $10.13, compared to a current price of $9.87 — trading 2.6% below its estimated fair value. The current Return-on-Tangible-Asset is 21.96%, which is 40% above median its 10-year median of 15.67 and 601.6% above the Drug Manufacturers industry median of 3.13. Haleon's overall GF Score™ is 70/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Haleon (HLN), the current Return-on-Tangible-Asset is 21.96% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Haleon (HLN) Overvalued in 2026?
Based on GuruFocus' analysis, Haleon stock appears to be undervalued.
The current stock price of $9.87 is trading 2.6% below its estimated GF Value™ of $10.13.
GuruFocus considers Haleon to be Fairly Valued.
Key valuation signals for HLN:
Return-on-Tangible-Asset: 21.96% (40% above median its 10-year median of 15.67)
GF Value™: $10.13 vs. price of $9.87 (2.6% below fair value)
Industry Position: 601.6% above the Drug Manufacturers median (#42 of 1009)
No single metric tells the full story. See the HLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.
70GF Score
Get the complete analysis for HLN
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HLN has been successfully added to your 
